The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus–related hepatocellular carcinoma
- Authors
- Lee, J.H.[Lee, J.H.]; Kim, B.K.[Kim, B.K.]; Park, S.Y.[Park, S.Y.]; Tak, W.Y.[Tak, W.Y.]; Park, J.Y.[Park, J.Y.]; Kim, D.Y.[Kim, D.Y.]; Ahn, S.H.[Ahn, S.H.]; Sinn, D.H.[Sinn, D.H.]; Kim, S.U.[Kim, S.U.]
- Issue Date
- Jul-2021
- Publisher
- Elsevier B.V.
- Keywords
- Entecavir; Tenofovir; Hepatocellular carcinoma; Curative; Treatment; Prognosis
- Citation
- EUROPEAN JOURNAL OF INTERNAL MEDICINE, v.89, pp.48 - 55
- Indexed
- SCIE
SCOPUS
- Journal Title
- EUROPEAN JOURNAL OF INTERNAL MEDICINE
- Volume
- 89
- Start Page
- 48
- End Page
- 55
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/24877
- DOI
- 10.1016/j.ejim.2021.02.019
- ISSN
- 0953-6205
- Abstract
- Background/aims: Whether entecavir (ETV) or tenofovir disoproxil fumarate (TDF) affords the better prognosis after curative treatment of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains unclear. We compared recurrence and death rates between patients taking ETV and those taking TDF. Methods: Between 2013 and 2017, patients with HBV-related HCC who had undergone hepatic resection (n=421) or radiofrequency ablation (n=305) as first-line anti-HCC treatment in three institutes were consecutively enrolled. All patients received ETV or TDF as a first-line antiviral. The cumulative probabilities of recurrence and death were assessed. We adjusted for viral factors, including the HBV-DNA load, and tumor and demographic factors. Results: During the study period (median 46.6 [interquartile range 25.3–58.9] months), 227 patients experienced recurrence and 53 died. In the ETV (n=405) and TDF (n=321) groups, the annual incidences of recurrence (10.61 and 11.21 per 100 person-years, respectively; P=727) and death (2.28 and 1.79 per 100 person-years, respectively; P=277) were similar, with adjusted hazard ratios (aHRs) of 0.932 (P=0.622) and 0.667 (P=0.193), respectively. When stratified by treatment modality and the timing of antiviral therapy commencement, the values were similar (all P>0.05). Inverse probability of treatment weighting (IPTW) analyses yielded results that were similar in the two groups in terms of recurrence (aHR=1.038, P=0.963) and death (aHR=0.799, P=0.431). Furthermore, the early (<2 years) and late (≥2 years) recurrence risks were not statistically different in the two groups (both P=0.400), as confirmed by IPTW analysis (P=0.502 and P=0.377, respectively). Conclusions: The prognoses in terms of recurrence and death after curative treatment of HBV-related HCC were not statistically different between the ETV and TDF groups. Further validation studies are needed. © 2021
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.